Histone Deacetylase Inhibitors (HDIs): Pharmacology, Uses and Health Effects

Beverly D. Carson (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED038000

Clear

$130.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Histone deacetylase inhibitors (HDIs) are good anti-cancer targets. Histone acetyltransferases (HATs) and HDIs play opposite roles in the regulation of gene expression via an epigenetic mechanism. HATs catalyze the acetylation of lysine residues in histone tails, facilitating and sustaining gene transcription. HDIs remove the acetyl moieties from the epsilon-amine of lysine residues of histone tails, leading to a more condensed form of chromatin and preventing gene transcription. This book focuses on the use of HDIs for the treatment of lymphoid malignancies; myeloid malignancies; and breast cancer. (Imprint: Nova Biomedical)

Preface

Classification and Function of Histone Deacetylase Inhibitors
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Histone Deacetylase Inhibitors in the Treatment of Lymphoid Malignancies
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Histone Deacetylase Inhibitors in the Treatment of Myeloid Malignancies
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Histone Deacetylase Inhibitors for Breast Cancer: Driving out of Stemness
(Marion A. Salvador, Daniel Birnbaum, Emmanuelle Charafe-Jauffret and Christophe Ginestier, Inserm, CRCM, Laboratoire d’Oncologie Moléculaire, Marseille, France, and others)

Index

You have not viewed any product yet.